Parisa Golriz Khatami1, Alireza Soleimani2, Nasrin Sharifi1, Esmat Aghadavod3, Zatollah Asemi4. 1. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. 2. Department of Internal Medicine, Kashan University of Medical Sciences, Kashan, Iran. 3. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: aghadavod_m@yahoo.com. 4. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: asemi_r@yahoo.com.
Abstract
BACKGROUND: Limited data are available that evaluated the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy (DN). OBJECTIVE: This study was conducted to evaluate the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with DN. METHODS: This randomized double-blind placebo-controlled clinical trial was carried out among 60 patients with DN. Patients were randomly allocated into two groups to take either 1200 IU/d of vitamin E supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were obtained at the onset of the study and after 12-week intervention to assess biomarkers of kidney injury, inflammation, and oxidative stress. RESULTS: After 12 weeks of intervention, compared with the placebo, vitamin E supplementation resulted in a significant increase in serum vitamin E levels (+42.3 ± 13.4 vs -0.8 ± 0.8 nmol/mL, P < .001) and a significant decrease in urine protein (-6.8 ± 4.3 vs -1.0 ± 8.0 mg/dL, P = .001) and protein-to-creatinine ratio (-0.2 ± 0.1 vs 0.0 ± 0.1, P < .001). In addition, a significant reduction in serum tumor necrosis factor-α (-35.4 ± 34.9 vs +5.6 ± 6.2 ng/L, P < .001), matrix metalloproteinase-2 (-556.7 ± 485.9 vs +60.4 ± 53.7 ng/mL, P < .001), matrix metalloproteinase-9 (-1461.5 ± 1456.0 vs +225.7 ± 488.2 ng/L, P < .001), malondialdehyde (-0.9 ± 0.5 vs +0.3 ± 0.4 μmol/L, P < .001), advanced glycation end products (-1832.2 ± 1941.6 vs +177.3 ± 324.1 arbitrary unit, P < .001), and insulin concentrations (-0.5 ± 2.7 vs +0.7 ± 1.0 μIU/mL, P = .03) was seen after the administration of vitamin E supplements compared with the placebo. Supplementation with vitamin E had no significant effects on other biomarkers of kidney injury, fasting plasma glucose, and insulin resistance compared with the placebo. CONCLUSION: Overall, our study demonstrated that oral high-dose vitamin E supplementation for 12 weeks among DN patients had favorable effects on biomarkers of kidney injury, inflammation, and oxidative stress.
RCT Entities:
BACKGROUND: Limited data are available that evaluated the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy (DN). OBJECTIVE: This study was conducted to evaluate the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with DN. METHODS: This randomized double-blind placebo-controlled clinical trial was carried out among 60 patients with DN. Patients were randomly allocated into two groups to take either 1200 IU/d of vitamin E supplements (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were obtained at the onset of the study and after 12-week intervention to assess biomarkers of kidney injury, inflammation, and oxidative stress. RESULTS: After 12 weeks of intervention, compared with the placebo, vitamin E supplementation resulted in a significant increase in serum vitamin E levels (+42.3 ± 13.4 vs -0.8 ± 0.8 nmol/mL, P < .001) and a significant decrease in urine protein (-6.8 ± 4.3 vs -1.0 ± 8.0 mg/dL, P = .001) and protein-to-creatinine ratio (-0.2 ± 0.1 vs 0.0 ± 0.1, P < .001). In addition, a significant reduction in serum tumor necrosis factor-α (-35.4 ± 34.9 vs +5.6 ± 6.2 ng/L, P < .001), matrix metalloproteinase-2 (-556.7 ± 485.9 vs +60.4 ± 53.7 ng/mL, P < .001), matrix metalloproteinase-9 (-1461.5 ± 1456.0 vs +225.7 ± 488.2 ng/L, P < .001), malondialdehyde (-0.9 ± 0.5 vs +0.3 ± 0.4 μmol/L, P < .001), advanced glycation end products (-1832.2 ± 1941.6 vs +177.3 ± 324.1 arbitrary unit, P < .001), and insulin concentrations (-0.5 ± 2.7 vs +0.7 ± 1.0 μIU/mL, P = .03) was seen after the administration of vitamin E supplements compared with the placebo. Supplementation with vitamin E had no significant effects on other biomarkers of kidney injury, fasting plasma glucose, and insulin resistance compared with the placebo. CONCLUSION: Overall, our study demonstrated that oral high-dose vitamin E supplementation for 12 weeks among DN patients had favorable effects on biomarkers of kidney injury, inflammation, and oxidative stress.
Authors: Esteban M Repetto; Morena Wiszniewski; Ana L Bonelli; Carolina V Vecino; Camila Martinez Calejman; Pablo Arias; Cora B Cymeryng Journal: Endocrine Date: 2018-09-21 Impact factor: 3.633
Authors: Rayne Gomes Amorim; Glaucevane da Silva Guedes; Sandra Mary de Lima Vasconcelos; Juliana Célia de Farias Santos Journal: Arq Bras Cardiol Date: 2019-06-06 Impact factor: 2.000